tiprankstipranks
Advertisement
Advertisement

ARMP Stock Latest News

Armata: Buy Rating Reiterated as AP-SA02 Advances Toward 2H26 Phase 3 Start; $15 Price Target Maintained
RatingsArmata: Buy Rating Reiterated as AP-SA02 Advances Toward 2H26 Phase 3 Start; $15 Price Target Maintained
12d ago
ARMP
Armata Pharmaceuticals Promotes David House to CFO
PremiumCompany Announcements
Armata Pharmaceuticals Promotes David House to CFO
1M ago
8K
ARMP
Armata Advances AP-SA02 Toward Phase 3 Trial Launch
PremiumCompany Announcements
Armata Advances AP-SA02 Toward Phase 3 Trial Launch
1M ago
8K
ARMP
Armata provides update on AP-SA02 studies
PremiumThe Fly
Armata provides update on AP-SA02 studies
1M ago
ARMP
Armata promotes David House to CFO
PremiumThe Fly
Armata promotes David House to CFO
1M ago
ARMP
FDA Pediatric Plan Milestone and Phase 3 Design Support Unchanged $15 Price Target and Buy Rating on Armata (ARMP)
PremiumRatingsFDA Pediatric Plan Milestone and Phase 3 Design Support Unchanged $15 Price Target and Buy Rating on Armata (ARMP)
1M ago
ARMP
Armata Advances AP-SA02 Pediatric Plan With FDA Agreement
Premium
Company Announcements
Armata Advances AP-SA02 Pediatric Plan With FDA Agreement
1M ago
8K
ARMP
Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02
Premium
The Fly
Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02
1M ago
ARMP
Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding
PremiumThe Fly
Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding
2M ago
ARMP
Armata gains new DoD funding for AP-SA02 advancement
PremiumCompany Announcements
Armata gains new DoD funding for AP-SA02 advancement
2M ago
8K
ARMP
Armata Shareholders Approve Directors, Executive Pay and Auditor
PremiumCompany Announcements
Armata Shareholders Approve Directors, Executive Pay and Auditor
2M ago
8K
ARMP
Analyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial
PremiumRatings
Analyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial
3M ago
ARMP
Armata Secures New Loan Amid Wider Quarterly Loss
PremiumCompany AnnouncementsArmata Secures New Loan Amid Wider Quarterly Loss
3M ago
8K
ARMP
Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year
Premium
The Fly
Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year
3M ago
ARMP
Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02
Premium
The Fly
Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02
4M ago
ARMP
Armata Gains FDA Fast Track for AP-SA02 Therapy
PremiumCompany Announcements
Armata Gains FDA Fast Track for AP-SA02 Therapy
4M ago
8K
ARMP
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors
PremiumCompany Announcements
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors
4M ago
8K
ARMP
Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch
PremiumThe Fly
Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch
5M ago
ARMP
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting
PremiumCompany Announcements
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting
5M ago
8K
ARMP
Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year
PremiumThe FlyArmata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year
5M ago
ARMP
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
Premium
Company Announcements
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
5M ago
8K
ARMP
Armata Pharmaceuticals delays announcement of Q4, FY25 results
Premium
The Fly
Armata Pharmaceuticals delays announcement of Q4, FY25 results
5M ago
ARMP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >